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Abstract: Obesity increases the risk for developing type 2 diabetes mellitus (T2DM) and this 
in turn correlates with an elevated probability of long-term diabetes complications once diabetes 
is established. Interventions aimed at lowering weight via changes in diet and lifestyle have 
repeatedly been shown to improve glycemic control in patients with T2DM and even to reverse 
early disease. Weight gain, a potential side effect of treatment for patients with T2DM, is also 
an important concern, and it has been noted that weight increases associated with antidiabetes 
therapy may blunt cardiovascular risk reductions achieved by decreasing blood glucose. Among 
older agents, metformin and acarbose have the lowest risk for weight gain, while sulfonylureas, 
meglitinides, and thiazolidinediones are all associated with weight increases. Clinical trial results 
have also consistently demonstrated that treatment with glucagon-like peptide-1 receptor ago-
nists and amylin lowers weight, and that dipeptidyl peptidase-4 inhibitors are weight neutral in 
patients with T2DM. Conventional human insulin formulations are known to increase weight in 
patients with T2DM. However, some insulin analogs, particularly insulin detemir, have lower 
liability for this adverse event. The use of both pharmacologic and surgical therapies aimed 
at treating obesity rather than lowering blood glucose have the potential to improve glycemic 
control and even resolve T2DM in some patients.
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Introduction
Obesity, along with other factors such as advancing age, family history of diabetes, 
history of gestational diabetes, impaired glucose metabolism, and physical inactiv-
ity, are associated with increased risk for type 2 diabetes (T2DM).1 It has been noted 
that the prevalence of diagnosed diabetes among adults 18–79 years of age in the 
USA increased by 41% from 1997 to 2003, and this increase was greatest among 
obese individuals (body mass index [BMI] $30 kg/m2).2 It is believed that obesity 
contributes to the development of T2DM by elevating levels of nonesterified free 
fatty acids, hormones, adipocytokines, and other substances that increase insulin 
resistance. Obesity-related elevation in proinflammatory molecules, including tumor 
necrosis factor-α and interleukin-6, are also believed to contribute to the development 
of both T2DM and metabolic syndrome.3 The prevalence of overweight and obesity 
among patients with T2DM are both extremely high. Results from the Study to Help 
Improve Early Evaluation and Management of Risk Factors Leading to Diabetes, for 
example, indicated that 28% of individuals surveyed with diabetes were overweight 
(BMI 25–29.99 kg/m2) and 59% were obese (defined as above) (Figure 1).4
Dovepress




open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/DMSO.S24022Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4
Obesity is not only associated with increased risk for the 
development of T2DM but also with elevated probability of 
long-term complications in people with this disease. The risk 
for these complications is also increased for obese patients 
in the prediabetic state.5,6 Patients with T2DM are at high 
risk for cardiovascular disease (CVD)-related events,7 and 
overweight/obesity and T2DM are both independent risk 
factors for the development of CVD.7,8 All of these results 
support the view that overweight/obesity, along with hyper-
glycemia and other risk factors such as elevated blood pres-
sure and abnormal lipids, act together to determine risk for 
all-cause and CVD mortality in patients with T2DM.9
There are also strong relationships among obesity, 
diabetes, and cancer risk. For example, meta-analysis of 
epidemiological data indicated that the relative risk (RR) 
for postmenopausal breast cancer is ∼1.5 for overweight 
women and .2 for obese women versus women with nor-
mal weight.10 The meta-analysis also found that diabetes is 
associated with postmenopausal breast cancer, with summary 
RRs from meta-analyses of 1.15–1.20. The risk for pancreatic 
cancer is also significantly increased by overweight or obesity 
or the presence of diabetes.11
Weight gain is also an important concern as a potential side 
effect of treatment for patients with, or at risk for, T2DM.12,13 
Control over body weight can significantly decrease the risk for 
complications in patients with T2DM and should be an impor-
tant aspect of management for these patients. This review con-
siders the importance of addressing obesity across the course 
of disease in patients with T2DM to decrease the risk for 
complications and optimize long-term outcomes. It includes 
consideration of diet and lifestyle management, effects of 
antidiabetes therapy on body weight, and both pharmacologic 
and surgical interventions aimed at lowering weight.
T2DM and overweight/obesity
Results from numerous large-scale long-term studies have 
indicated that excess weight is harmful in patients with or 
without T2DM. Results from the Framingham Study showed 
that atherosclerotic risk factor clustering is common in both 
men and women in the general population, worsens with weight 
gain, and is associated with increased risk of coronary heart 
disease. This prospective study of 2406 men and 2569 women 
aged 18–74 years at baseline indicated that a 2.25 kg increase 
in weight over 16 years was associated with a 20% rise in the 
summed severity of six CVD risk factors (high-density lipopro-
tein cholesterol [HDL-C], total cholesterol, BMI, systolic blood 
pressure, triglycerides, and plasma glucose) in men and a 37% 
increase in women.14 The importance of obesity in increasing 
the risk for diabetes complications was underscored by the 
Heart Outcomes Prevention Evaluation study. Results from this 
4.5-year study of 6620 men and 2182 women (about 32% with 
diabetes) showed that obesity, in particular, abdominal adipos-
ity, leads to an increased risk for CVD, including myocardial 
infarction by 23% (P , 0.01), congestive heart failure by 38% 
(P , 0.03), and all-cause mortality by 17% (P , 0.05).15
Given the highly negative effects of obesity in patients 
with or without T2DM, it is not surprising that several stud-
ies have demonstrated significant benefits of weight loss for 
improving glycemic control and reducing risk for diabetes 
complications and mortality. One-year results of the Look 
AHEAD (Action for Health in Diabetes) trial showed that 
clinically significant weight loss in patients with T2DM 
was associated with improved glycemic control and a more 
favorable CVD risk profile.16 This study of 5145 individu-
als with T2DM showed that intensive lifestyle intervention, 
which produced a mean 8.6% reduction in body weight, was 
associated with a significant decrease in mean hemoglobin 
A1c (HbA1c) from 7.3% to 6.6% (−0.64 ± 0.02; P , 0.001), 
significant decreases in systolic (−6.8 ± 0.4; P , 0.001) and 
diastolic (−3.0 ± 0.2; P , 0.001) blood pressure and triglyc-
erides (−30.3 ± 2.0; P , 0.001), and significant increases in 
HDL-C (+3.4 ± 0.2; P , 0.001).16 Similarly, a 2-year study 
of weight reduction achieved via weight-loss diets in mod-
erately obese individuals (14% with T2DM) showed that a 
low-carbohydrate diet resulted in a 20% decrease in the ratio 
of total cholesterol to HDL-C and a 4.7 ± 6.5 kg decrease in 
body weight, and that a Mediterranean diet decreased fasting 
glucose in patients with T2DM by 32.8 mg/dL (1.82 mmol/L) 
and body weight by 4.4 ± 6.0 kg.17 Results obtained after 
Figure 1 Distribution of body mass index (BMi) values for patients with type 1 or 
type 2 diabetes mellitus in the Study to Help improve Early Evaluation and Management 
of Risk Factors Leading to Diabetes.
Note: Copyright © 2007.  John Wiley and Sons. Reproduced with permission from 
Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes 
mellitus,  hypertension  and  dyslipidaemia:  comparison  of  data  from  two  national 
surveys. Int J Clin Pract. 2007;61(5): 737–747.4
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4 years of the ongoing Look AHEAD trial revealed that, 
among those with T2DM, intensive lifestyle intervention can 
provide sustained weight loss along with improvements in 
fitness, glycemic control, and CVD risk factors.18
Results from a prospective analysis of data from 4970 over-
weight individuals with diabetes enrolled in the American Cancer 
Society’s Cancer Prevention Study I with a 12-year mortality 
follow-up indicated that 34% of the study cohort reported inten-
tional weight loss (based on reply to a questionnaire with the fol-
lowing as choices: “unintentional” loss or gain, “intentional” loss 
or gain, or “no change”). Intentional weight loss was associated 
with a 25% reduction in total mortality and a 28% reduction in 
diabetes- and CVD-related mortality.19 Data from the weight loss 
arm of the Trials of Hypertension Prevention showed that even 
modest weight loss (4.4 kg at 6 months, 2.0 kg at 18 months, and 
0.2 kg at 36 months) led to clinically significant long-term risk 
reductions for hypertension 0.58 (95% confidence interval [CI] 
0.36–0.94) at 6 months, 0.78 (95% CI 0.62–1.00) at 18 months, 
and 0.81 (95% CI 0.70–0.95) at 36 months.20
Effective intervention to decrease obesity can also lower 
the occurrence of diabetes in at-risk individuals. Results from 
the Malmo study that included 41 subjects with early T2DM 
and 181 with impaired glucose tolerance (IGT) indicated 
that an intervention focused on diet and exercise normalized 
glucose tolerance in .50% of subjects with IGT and reversed 
T2DM in .50% of those diagnosed with early disease over 
6 years of follow-up.21 A second small-scale study random-
ized (4:1) male health-screening examinees with IGT to 
standard treatment (n = 356) or an intensive intervention 
group that included detailed instructions on lifestyle that were 
repeated every 3–4 months during hospital visits. The cumu-
lative 4-year incidence of diabetes was 9.3% in the control 
group versus 3.0% in the intervention group (P , 0.001).22 
The Diabetes Prevention Program included 1079 nondia-
betic participants, with IGT and a mean baseline BMI of 
33.9 kg/m2, who were randomized to intensive lifestyle inter-
vention and followed for 3.2 years. Results from this group of 
patients showed that each 1 kg of weight loss was associated 
with a 16% reduction in the risk for development of T2DM.23 
Similarly, findings from a Cochrane meta-analysis of eight 
controlled trials indicated that interventions aimed at increas-
ing exercise combined with diet modification reduced the 
risk of T2DM compared with standard recommendations in 
high-risk groups (people with IGT or metabolic syndrome) 
(RR 0.63; 95% CI 0.49–0.79). This intervention improved 
systolic (weighted mean difference −4 mmHg; 95% CI −5 
to −2) and diastolic (−2 mmHg; 95% CI −3 to −1) blood 
pressure levels, respectively.24
All of these results support the American Diabetes 
  Association (ADA), North American Association for the Study 
of  Obesity (now known as The Obesity Society), and American 
Society for Clinical Nutrition guidelines, which indicate that 
moderate weight loss (5% of body weight) can decrease insulin 
resistance, decrease fasting blood glucose, and reduce the need 
for antidiabetes medications.25 ADA guidelines published in 
2011 also recommend such weight loss, and note that 7% 
reduction along with regular physical activity (150 minutes/
week) can reduce the risk for developing diabetes.26
Selection of treatment across  
the spectrum of disease in T2DM
The two major US treatment algorithms for antidiabetes ther-
apy in patients with T2DM differ substantially. The consensus 
statement from the ADA/European Association for the Study of 
Diabetes recommends a stepwise approach to treatment, with 
initial therapy consisting of diet and lifestyle changes plus met-
formin and subsequent treatment with sulfonylurea or insulin to 
achieve HbA1c , 7%.27 In contrast, the American Association of 
Clinical Endocrinologists/American College of Endocrinology 
consensus panel recommends more aggressive, individualized 
combination therapy with a wider range of agents (eg, met-
formin, thiazolidinediones, incretin-based treatments, insulin) 
as initial pharmacotherapy for patients with T2DM to achieve   
HbA1c , 6.5%.28 Both guidelines emphasize the importance 
of diet and lifestyle modification as an essential part of 
treatment.27,28
Dietary intervention
The emphasis on diet and lifestyle intervention in newly 
diagnosed patients with T2DM is supported by results from 
several clinical trials. Results from the Look AHEAD study 
showed that 1 year of diet and exercise aimed at weight loss 
improved glucose disposal rate, fasting plasma glucose, free 
fatty acids, and adipose tissue distribution in a small cohort 
of 26 men (mean baseline BMI 32.4 kg/m2) and 32 women 
(mean baseline BMI 34.8 kg/m2) with T2DM. Results from 
this study also showed that changes in overall weight (adipose 
tissue mass) and hepatic fat were the most important deter-
minants of metabolic improvements in these patients.29
A meta-analysis of eleven randomized controlled trials 
that included 402 patients with T1DM or T2DM indicated 
that although each of those studies had unique criteria for 
identifying either low or high glycemic indexes, those consid-
ered low significantly decreased HbA1c with a weighted mean 
difference of −0.5% (95% CI −0.9 to −0.1; P = 0.02) versus 
high-glycemic-index diets. Results from this   meta-analysis 
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also showed that a low-glycemic-index diet significantly 
decreased episodes of hypoglycemia versus a high-glycemic-
index diet in one study (difference of −0.8 episodes per 
patient per month; P , 0.01).30
In considering these results, it is important to note that 
different types of diets have distinct effects on weight loss in 
patients with T2DM. Diets that might be considered include 
low fat, high protein/low carbohydrate (ketogenic and nonketo-
genic), low glycemic-index, and very low   calorie regimens. A 
clinical comparison of low-fat, restricted-calorie; Mediterranean, 
restricted-calorie; and low-carbohydrate,   nonrestricted-calorie 
diets indicated that all decreased weight (2.9 kg, 4.4 kg, and 
4.7 kg, respectively) in moderately obese patients, (mean 
baseline BMI 31 kg/m2) but that the low-carbohydrate diet 
had more favorable effects on lipids and the Mediterranean 
diet had more favorable effects on glycemic control.17 Both 
low-glycemic-index and low-carbohydrate ketogenic diets 
(,20 g carbohydrate/day) have been shown to lower both 
HbA1c and body weight in patients with T2DM, but the 
reductions with the ketogenic diet were significantly greater 
than those with the low-glycemic-index diet (1.5% versus 
0.5%; P = 0.03 and 11.1 kg versus 6.9 kg; P = 0.008).31 
A low-carbohydrate nonketogenic diet (30% protein, 50% 
fat, and 20% carbohydrate) has also been shown to be effec-
tive for lowering fasting glucose by 40% and HbA1c by 1.7% 
versus a standard diet in patients with T2DM.32 A very low 
calorie diet (450 calories/day) has also been shown to be 
effective in patients with T2DM. Results from one study 
of 18 patients who followed this diet for 30 days indicated 
an 11.7 kg reduction in body weight over this period, and 
improvements in serum lipids, blood pressure, and glycemia 
that were sustained over 18 months.33
Conventional oral antidiabetes therapy
Conventional oral antidiabetes agents include metformin, 
sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and 
thiazolidinediones (Table 1).27,34 One or more of these agents 
are generally employed, along with dietary and lifestyle inter-
vention, as initial therapy for patients with T2DM, with varying 
effects on body weight and, potentially, CVD risk.13,27,35
Metformin
The action of metformin is reduction of hepatic glucose output 
and reduction of fasting blood glucose levels.27 Treatment 
with metformin results in HbA1c reductions of 1.0%–2.0%.27 
  Metformin has a favorable profile with respect to body weight 
and other CVD risk factors. It does not cause weight gain and it 
improves both the blood lipid profile and fibrinolytic activity.13 
Results from one study indicated that 1 year of treatment 
with metformin decreased triglycerides from baseline by 
26.6 mg/dL (0.3 mmol/L) and low-density lipoprotein cho-
lesterol [LDL-C] by 4.6 mg/dL (0.12 mmol/L), and increased 
HDL-C by 3.1 mg/dL (0.08 mmol/L).36 Weight loss in patients 
with T2DM taking metformin is associated with reductions in 
both total body fat and visceral fat in those with abdominal or 
visceral obesity.37 Results from one study in which patients 
were treated with metformin (1000 mg/day) for 26 weeks indi-
cated that mean body weight decreased by 2.0 kg (P , 0.05 
versus placebo), abdominal subcutaneous fat decreased by 
0.4 kg, and intraabdominal fat decreased by 0.3 kg (both 
P , 0.05 versus baseline).38 Metformin is associated with 
gastrointestinal side effects and is contraindicated in patients 
with renal insufficiency.27
Table 1 Oral antihyperglycemic medications available in the USA
Class Medication
Biguanides • Liquid metformina (Riomet®) 
• Metforminb (Glucophage®) 
•   Metformin extended-releaseb (Glucophage 
XR®, Fortamet®, Glumetza®)




• Acarbose (Precose®) 
• Miglitol (Glyset®)
insulin secretagogues • Sulfonylureas 
   – Glimepirideb (Amaryl®) 
   – Glipizideb (Glucotrol®) 
   – Glipizide extended-release (Glucotrol XL®) 
   – Glyburideb (Micronase®, Diabeta®) 
   – Micronized glyburide (Glynase®) 
• Nonsulfonylurea meglitinides 
   – Repaglinide (Prandin®) 
• D-phenylalanine derivatives 
   – Nateglinide (Starlix®)
DPP-4 inhibitors • Sitagliptin (Januvia®) 
• Saxagliptin (Onglyza™)
Bile acid sequestrant • Colesevelam (Welchol®)
Fixed combinations • Metformin and glipizide (Metaglip®) 
• Metformin and glyburide (Glucovance®) 
• Metformin and pioglitazone (ACTOplus met®) 
• Pioglitazone and glimepiride (Duetact®) 
• Rosiglitazone and glimepiride (Avandaryl®)c 
• Rosiglitazone and metformin (Avandamet®)c 
• Sitagliptin and metformin (Janumet®) 
• Repaglinide and metformin (PrandiMet®)
Notes: aLiquid formulation for patients unable to swallow pills; bAvailable as a generic 
medication;  cOn September 23, 2010, the Food and Drug Administration (FDA) 
announced  regulatory  actions  with  respect  to  products  containing  rosiglitazone. 
The FDA is requiring GlaxoSmithKline (GSK) to implement restrictions on the use 
of these products through a program to assure their safe use and additional safety 
labeling changes in response to the agency’s review of data that suggest an elevated 
risk of cardiovascular events. Adapted with permission from Joslin Clinical Guideline for 
Pharmacological Management of Type 2 Diabetes, copyright © 2009 (updated 11/2010) 
by Joslin Diabetes Center (www.joslin.org). All rights reserved.34
Abbreviation: DPP-4, dipeptidyl peptidase-iv.
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Sulfonylureas
Sulfonylureas lower glycemia by enhancing insulin secretion 
and their use can lower HbA1c by 1.0%–2.0%.27 Despite the 
fact that sulfonylureas are still recommended for the treat-
ment of T2DM, the use of these agents is being called into 
  question. Results from a study of 9876 patients with T2DM 
who were treated with oral glucose-lowering drugs after a 
myocardial infarction indicated that the risk for cardiovascular 
mortality was significantly increased (hazard ratio [HR] 1.28; 
95% CI 1.14–1.44) versus those who received   metformin.39 
Results from a second retrospective cohort that included 
34,253 patients treated with a sulfonylurea, metformin, 
rosiglitazone, or pioglitazone in a single academic health care 
network indicated that the RR for myocardial infarction for 
those receiving a sulfonylurea was 2.2 (95% CI 1.6–3.1) 
compared with metformin.40 Results from a cohort of 205 
adult men with T2DM who were followed for a mean of 
9.4 years indicated that those treated with a sulfonylureas 
alone experienced a mean weight gain of 0.42 kg/year,41 
and it is reasonable to suggest that increased cardiovascular 
risk with sulfonylureas may be related to the weight gain 
in patients treated with these drugs. Sulfonylureas are also 
associated with potentially severe hypoglycemic events.27
Meglitinides
Like sulfonylureas, meglitinides bind to sulfonylurea recep-
tors on pancreatic β-cells (although at a different receptor 
site) to stimulate insulin secretion. These drugs have shorter 
half-lives than sulfonylureas and must be administered more 
often, but they do result in HbA1c reductions of 0.5%–1.5%.27 
Meglitinides are also associated with significant weight gain 
(2.4 kg over 3 months; P , 0.05) versus metformin when 
used for the treatment of patients with T2DM;42 results from a 
meta-analysis of 15 clinical trial results for this class indicated 
that weight gains as high as 3 kg may occur over 3 months.43 
Meglitinides have also been associated with hypoglycemia, 
but with a frequency lower than that for sulfonylureas.27
Alpha-glucosidase inhibitors
Alpha-glucosidase inhibitors slow digestion of polysac-
charides in the proximal small intestine. This results in 
lowering of HbA1c by 0.5%–0.8% and decreased postpran-
dial glucose levels with low risk for hypoglycemia.27 The 
alpha-glucosidase inhibitor acarbose decreased HbA1c by 
0.8% (95% CI −0.9 to −0.7), according to a meta-analysis of 
30 acarbose trials, and was not associated with weight gain 
in patients with T2DM.44 It has been shown to decrease the 
risks for progression to diabetes and CVD events in patients 
with IGT who were treated for a mean of 3.3 years in the 
Study to Prevent Non-Insulin Dependent DM trial. Results 
from this study indicated that acarbose treatment resulted 
in a 25% RR reduction in the development of T2DM (95% 
CI 0.63–0.90; P = 0.0015), and a 49% decrease in risk for 
CVD events (95% CI 0.28–0.95; P = 0.03).45 Miglitol, which 
is the other alpha-glucosidase inhibitor, has been shown to 
provide similar reductions in HbA1c but is associated with 
abdominal discomfort.46,47 The hypoglycemic potency of 
alpha-glucosidase inhibitors is less than that of either bigu-
anides or sulfonylureas.13 Unfortunately, those treatments are 
associated with gastrointestinal side effects that have resulted 
in limited use within the US.
Thiazolidinediones
Thiazolidinediones are modulators of peroxisome proliferator-
activated receptor γ modulators that increase the insulin 
sensitivity of muscle, fat, and liver.27 These drugs lower 
plasma glucose by enhancing its uptake into tissues and 
decrease HbA1c by 0.5%–1.4%.27 In adipose tissue, thiazoli-
dinediones act as insulin sensitizers and are potent inhibitors 
of lipolysis, and they enable mobilization of fat from muscle 
and liver tissues as well as β-cells. These actions result in 
amelioration of lipotoxicity and improve insulin sensitiv-
ity by reducing insulin secretion, which helps to preserve 
β-cell function and therefore maintain glycemic control 
over time.48 Thiazolidinediones are associated with weight 
gain and edema as well as increased risk for congestive heart 
failure.27 Results from a meta-analysis of four randomized 
trials that included 14,291 patients (6421 receiving rosigli-
tazone, 7870 receiving control therapy) with follow-up of 
1–4 years indicated that rosiglitazone significantly increased 
the risk of myocardial infarction (RR 1.42; P = 0.02) and 
heart failure (RR 2.09; P , 0.001), but not CVD mortality 
(RR 0.90; P = 0.53).49 A recent study that directly compared 
risks for acute myocardial infarction, acute heart failure, or 
all-cause mortality among patients $18 years of age who 
started treatment with rosiglitazone (n = 6421) or pioglita-
zone (n = 7870) between January 1, 2001, and December 12, 
2005 indicated that 4.16% of the patients treated with 
rosiglitazone experienced acute myocardial infarction, acute 
heart failure, or death versus 4.14% of those treated with 
pioglitazone (HR 1.03; 95% CI 0.91–1.15; P = 0.666) over a 
median follow-up period of 34 months.50 In considering these 
results, it is worth noting that the 10-year risk for coronary 
heart disease in patients with T2DM is about 13%.51 It has 
also been shown that thiazolidinediones cause bone loss and 
increase fracture risk in patients with T2DM.52 Recent results 
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have also indicated that long-term treatment with pioglitazone 
may be associated with increased risk for bladder cancer. A 
study that included 193,099 patients in the Kaiser Permanente 
Northern California diabetes registry indicated that any use of 
pioglitazone was not associated with elevated risk of bladder 
cancer (P = 0.8). However, there was an increased risk (HR 
1.4; 95% CI 1.03–2.0) in patients who used pioglitazone for 
.24 months.53
incretin-based treatments
Incretins – glucagon-like peptide (GLP)-1 receptor ago-
nists and dipeptidyl peptidase (DPP)-4 inhibitors (Tables 1 
and 2)27,34,54 – have become increasingly accepted as treat-
ments for patients with T2DM, and their effects on body 
weight differ from those of conventional oral therapies.55 Sev-
eral mechanisms contribute to the glucose-lowering effects of 
GLP-1 receptor agonists. These include glucose-dependent 
stimulation of insulin secretion, reduction of plasma glucagon 
concentrations, and delay of gastric emptying. These agents 
lower HbA1c by 0.5%–1.0%.27 The weight loss associated 
with these agents is believed to result from delayed gastric 
emptying which maintains a feeling of fullness, thus reducing 
appetite and food intake as well as the signaling of satiety via 
direct stimulation of parts of the brain involved in regulation 
of appetite.56 Meta-analyses of results from 21 random-
ized controlled trials revealed that patients who received 
GLP-1 receptor agonists (n = 5429) had significant reduc-
tions in BMI compared to those treated with placebo 
(difference −0.44 kg/m2; P = 0.012) and those who received 
insulin (difference −1.57 kg/m2; P , 0.001).57 Meta-analyses 
of results from eight trials in which GLP-1 receptor agonists 
were compared with oral antidiabetes agents indicated signifi-
cantly greater weight loss with the incretin mimetics versus 
comparators (weighted mean difference −2.37 kg; 95% 
CI −3.95 to −0.78).58 Direct comparison of the two currently 
approved GLP-1 receptor agonists indicated that liraglutide 
and exenatide were associated with similar weight reductions 
(3.24 kg versus 2.87 kg, respectively; P = 0.2235). However, 
liraglutide decreased mean HbA1c to a greater extent than 
exenatide (1.12% versus 0.79%; P , 0.0001).59 Analysis of 
results from studies of liraglutide have shown that the reduc-
tion in body weight in patients treated with this agent results 
primarily from decreases in both subcutaneous and visceral 
adipose tissue.60 The most common adverse events associated 
with GLP-1 receptor agonists are gastrointestinal events. 
Long-term treatment of rodents with liraglutide was found 
to cause thyroid C-cell hyperplasia,61 but clinical results 
have not indicated any increased risk for medullary thyroid 
cancer.54 It has been reported that eight cases of acute pan-
creatitis occurred during clinical development of exenatide 
and there were 36 postmarketing reports of acute pancreatitis 
in exenatide-treated patients. Four patients developed acute 
or chronic pancreatitis during liraglutide clinical trials.62
Systematic reviews of clinical results for DPP-4 inhibitors 
indicated that these agents lower HbA1c by 0.5%–0.8% and 
are generally weight-neutral.27,63,64 Since these drugs act via 
increasing the duration of action of GLP-1, they have low risk 
for hypoglycemia. DPP-4 inhibitors are available as fixed-
dose combinations with metformin. It has been suggested 
that DPP-4 inhibitors have the potential to interfere with 
immune function and have been associated with increased 
risk for upper respiratory infections.27 Evaluation of clinical 
trial results for sitagliptin has also shown that it is not asso-
ciated with an increase in risk for cardiovascular events.65 
A trial designed to compare the efficacy of liraglutide and 
sitagliptin published in 2010 reported more substantial 
reductions in HbA1c among patients who received 1.8 mg 
liraglutide (−1.50%; 95% CI −1.63 to −1.37) and 1.2 mg 
liraglutide (−1.24%; 95% CI −1.37 to −1.11; n = 221) than 
those treated with sitagliptin (−0.90%; 95% CI −1.03 to 
−0.77; n = 219).66
Pramlintide
Pramlintide, an amylinomimetic, is approved for treatment of 
elevated postprandial glucose levels in T1DM and T2DM.67 
Combined analysis of four studies of pramlintide in patients 
with T2DM indicated that it significantly reduced HbA1c by 
0.33% (95% CI 0.14–0.51; P = 0.004) and weight by 2.57 kg 
(95% CI 1.70–3.44; P , 0.00001) versus controls.68 The 
adverse events observed most often with pramlintide are 
nausea and hypoglycemia.69
Novel therapy
A new class of glucose-lowering agents that are of particular 
interest because of their favorable effects on body weight are 
sodium-glucose co-transporter 2 inhibitors. These agents 
decrease the reabsorption of glucose and thus increase 
renal glucose excretion.70 Results from a clinical study of 
dapagliflozin 2.5 mg, 5 mg, or 10 mg versus placebo indi-
cated HbA1c reductions of 0.58%, 0.63%, and 0.82% versus 
0.13%, respectively. Reductions in body weight were 1.18 kg, 
1.56 kg, and 2.26 kg versus 0.72 kg, respectively.71 Treatment 
with sodium-glucose co-transporter 2 inhibitors has been 
shown to be associated with increased risk for urinary tract 
and genital infections.71 Concern about the safety of dapagli-
flozin has been raised by results indicating that nine of 5478 
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patients taking dapagliflozin in clinical trials had bladder 
cancer, compared with one of 3156 patients in the placebo 
group. In addition, nine of 2223 women taking dapagliflozin 
had breast cancer, compared with one of 1053 women in the 
placebo group.72,73
insulin treatment
A very large percentage of patients with T2DM ultimately 
require insulin therapy (see Table 2 for examples)34 to main-
tain control over blood glucose.48,74 Insulin remains the most 
potent medication currently available to achieve tight control 
over plasma glucose and avoid or delay long-term disease 
complications among nonhospitalized patients. However, 
insulin treatment is commonly associated with weight 
gain,75 which varies substantially with the type of insulin 
employed for treatment (see below). This may be due in part 
to improved glycemic control resulting in decreased glycosu-
ria, resulting in more glucose absorption and therefore more 
calories retained. Defensive snacking behaviors, driven by 
fears of hypoglycemia, can also contribute to weight gain in 
patients using insulin.74 Insulin also has anabolic effects, and 
this is reflected by the fact that patients with diabetes gain 
lean as well as fat mass. Results from two studies indicated 
that 30%–37% of the weight gain associated with insulin 
treatment was lean mass.76,77
Treatment with an older and commonly used insulin 
preparation, neutral protamine Hagedorn (NPH) insulin, has 
been consistently associated with weight gain. Results from 
one study of insulin therapy in patients with T2DM indi-
cated that patients gained 3.8 kg over 6 months of treatment 
and most of this gain was fat mass.78 This complication of 
treatment with NPH is significantly decreased with insulin 
analogs. Meta-analysis of clinical trial results (Figure 2)79 
indicated that the long-acting insulin analog detemir was 
associated with less weight gain than NPH insulin in 
patients with diabetes, although the insulin analog glargine 
was not (standardized mean difference detemir versus 
glargine −0.37 kg; P = 0.048).79 Another meta-analysis of 
trials found more weight gain with glargine than NPH (pooled 
mean change −0.33 kg; 95% CI −0.61 to −0.06).80
Results from several large-scale clinical trials demonstrated 
the significantly superior effects of insulin detemir on weight 
gain versus NPH insulin and insulin glargine. Results from a 
24-week study in which either insulin detemir or NPH insulin 
was added to oral antidiabetes therapy in 476 patients with 
T2DM indicated a 1.2 kg weight gain with insulin detemir 
versus 2.8 kg with NPH insulin (P , 0.001).81 Results 
from a 26-week, randomized, controlled trial that included 
271 patients with T2DM who received either insulin detemir 
or NPH insulin once daily in the evening along with mealtime 
insulin aspart substituted for two daily doses of insulin (at least 
one had to be a premix) indicated that weight had increased 
significantly less with detemir (0.4 kg) than with NPH (1.9 kg) 
(P , 0.0001) at the end of the study.82 Another 26-week trial 
compared insulin detemir and NPH insulin in 505 patients 
with T2DM who also received insulin aspart at mealtimes. 
After 26 weeks of treatment, patients receiving insulin detemir 
gained significantly less weight (1.0 kg) than those who were 
administered NPH insulin (1.8 kg) (P = 0.017).83 A 26-week 
comparison of insulins detemir and glargine in 385 patients 
with T2DM who also received mealtime insulin aspart in a 
basal-bolus regimen showed that there was further significantly 
less weight gain with insulin detemir (1.2 kg) versus insulin 
glargine (2.7 kg) (P = 0.001).84 The reason for decreased 
weight gain in patients treated with long-acting insulin detemir 
has not been elucidated, but results from several studies have 
suggested possible explanations. It may be that acylation and 
albumin binding used to extend the duration of action for 
insulin detemir results in a greater influence on hepatocytes 
than peripheral tissues. This might reduce glucose output 
from the liver without promoting peripheral lipogenesis.85 An 
effect of insulin detemir in the central nervous system may 
also contribute to its decreased risk for weight gain versus 
NPH insulin and insulin glargine. A study in 15 healthy vol-
unteers showed that a bolus injection of insulin detemir during 
hyperinsulinemic-euglycemic clamp produced a change in the 
electroencephalogram not observed after injection of regular 
human insulin. Results from this study also showed that insu-
lin detemir significantly decreased subsequent food intake by 
303 kcal versus regular human insulin (P , 0.04).86
The pharmacokinetic/pharmacodynamic profile for insulin 
detemir may also contribute to the favorable effects of this 
agent on body weight. Insulin detemir has a flatter time-
action profile versus NPH insulin, providing more consistent 
plasma levels.87 The pharmacokinetic and pharmacodynamic 
within-subject variation is lower for insulin detemir versus 
glargine,88 and this may also contribute to lower weight gain 
during treatment.
Adjunctive therapies for management 
of body weight in patients with 
T2DM
Pharmacotherapy
The close association between obesity and T2DM suggests 
that a more proactive approach to weight management in 
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obese individuals without diabetes may have the potential 
to delay or possibly prevent the onset of T2DM. In patients 
who already have diabetes, better control of weight has the 
potential to decrease glucose levels. However, development 
of pharmacologic agents to manage obesity has been difficult, 
with many being denied approval and only a few currently 
in the pipeline (Table 3).89
Orlistat blocks absorption of ingested fat by inhibiting 
pancreatic lipase and it is approved for use in adults and 
children $12 years of age for up to 1 year.90 Meta-analysis 
of results from 29 controlled clinical trials of orlistat has 
indicated that it produces a mean 2.75 kg weight loss over 
52 weeks of treatment.91 Systematic review of 28 clinical 
trials for orlistat has also shown that it has significant benefit 
in improving the lipid profile in patients with diabetes, with 
significant (P , 0.05) reductions versus placebo in total cho-
lesterol (weighted mean difference −0.37 mmol/L) and LDL-C 
(−0.27 mmol/L).92 Results from a 4-year   prospective study that 
Table 2 injectable diabetes medications available in the USA: (A) insulins and (B) incretin mimetics and noninsulin synthetic analogs
A) Insulin type Product Onseta Peaka Durationa
Rapid acting
insulin aspart analog NovoLog® 10–30 min 30 min–3 h 3–5 h
insulin glulisine analog Apidra® 10–30 min 30 min–3 h 3–5 h
insulin lispro analog Humalog® 10–30 min 30 min–3 h 3–5 h
Short acting
Human regular insulin • Humulin R® 
• Novolin R®
30–60 min 2–5 h Up to 12 hb
Intermediate acting
Human NPH insulin • Humulin N® 
• Novolin N®
90 min–4 h 4–12 h Up to 24 hc
Long acting
insulin detemir Levemir® 45 min–4 h Minimal peak Up to 24 hd
insulin glargine Lantus® 45 min–4 h Minimal peak Up to 24 hd
Premixed insulin combinations
50% NPH; 50% regular Humulin 50/50®
70% NPH; 30% regular Humulin 70/30®
70% NPH; 30% regular Novolin 70/30®
50% lispro protamine suspension, 50% lispro Humalog Mix 50/50®
50% aspart protamine suspension, 50% aspart Novolog Mix 50/50®
75% lispro protamine suspension, 25% lispro Humalog Mix 75/25®
70% aspart protamine suspension, 30% aspart NovoLog Mix 70/30®
B)   Incretin mimetics and noninsulin  
synthetic analogs
Mechanism of action Type  
of diabetes
# of injections/day
Exenatide (Byetta®) incretin mimetic that enhances  
glucose-dependent insulin secretion  
and several other antihyperglycemic  
actions of incretins.
2 2
Liraglutide (victoza®) A GLP-1 receptor agonist  
indicated as an adjunct to diet  
and exercise to improve  
glycemic control.
2 1 (independent of meals)
Pramlintide (Symlin®) Synthetic analog of human amylin,  
a naturally occurring hormone  
made in the β-cells, which slows  
gastric emptying, suppresses  
glucagon secretion, and regulates  
food intake. A significant reduction  
in insulin dose may be required  
when insulin is used in conjunction  
with pramlintide.
1 and 2 1–4 (with meals)
Notes: aThe onset, peak, and duration of any insulin type depends on many factors. Patients may experience variations in timing and/or intensity of insulin activity due 
to dose, site of injection, temperature of the insulin, level of physical activity, in addition to other factors;  bUsual clinical relevance can be less than 12 hours;  cUsual 
clinical relevance can be less than 24 hours. Often requires twice-daily dosing. dIndividual response may require twice-daily dosing. Adapted with permission from Joslin 
Clinical Guideline for Pharmacological Management of Type 2 Diabetes, copyright © 2009 (updated 11/2010) by Joslin Diabetes Center (www.joslin.org). All rights reserved.34 
Abbreviations: GLP-1, glucagon-like peptide-1; h, hours; min, minutes; NPH, neutral protamine Hagedorn; #, number.
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included 3305 patients (BMI $ 30 kg/m2 and normal [79%] 
or IGT [21%]) indicated that the cumulative incidence of 
diabetes was 6.2% for orlistat and 9.0% with placebo (37.3% 
risk reduction; P = 0.0032).93 Cetilistat is a novel inhibitor of 
gastrointestinal and pancreatic lipases that has proceeded to 
Phase III development. A 14-week (12 weeks of active treat-
ment) study included 612 overweight or obese patients (mean 
baseline BMI 34.3 kg/m2) with T2DM who were randomized 
to cetilistat (40 mg, 80 mg, or 120 mg three times daily), or 
orlistat (120 mg three times daily). Study results indicated 
similar reductions in body weight of 3.78–4.32 kg for patients 
treated with 80 mg or 120 mg cetilistat or 120 mg orlistat (all 
P # 0.01 versus baseline).94
Other agents currently approved for treatment of obesity 
(each for up to 12 weeks in adults) include phentermine, 
diethylpropion, and phendimetrazine.90 Meta-analysis of 
results from nine clinical trials with phentermine indicated 
that it decreased mean body weight by 3.6 kg over 2–24 weeks 
of treatment,91 but it has not been specifically evaluated in 
patients with T2DM in a large-scale controlled clinical trial. 
Meta-analysis of results from 13 clinical trials of diethylpro-
pion indicate a mean weight reduction of 3.0 kg among obese 
individuals in studies of 6–52 weeks duration.91 Phendime-
trazine has been shown to result in weight loss of 2.5–5.5 kg 
over an unspecified period in overweight patients.95
While other agents or combinations have been developed 
for the treatment of obesity, none are currently approved by 
the Food and Drug Administration (FDA). Sibutramine acts 
principally by blocking synaptic reuptake of serotonin and 
noradrenaline;96 meta-analysis of results from eight controlled 
clinical trials of sibutramine in patients with T2DM indicated 
that decreases in body weight and waist circumference were 
significantly greater with this agent versus placebo, but 
sibutramine had minimal effects on glycemic control or lipids. 
This agent was recently withdrawn from the market in the US 
due to increased risk for myocardial infarction and stroke,97 as 
reported in the Sibutramine Cardiovascular Outcome Trial.98,99 
Abbott Laboratories (Abbott Park, IL), the manufacturer of 
sibutramine, also withdrew sibutramine from other countries 
and has suspended all activities related to it.100
Lorcaserin is a selective serotonin receptor agonist that 
was also developed for the treatment of obesity.100 The effi-
cacy of lorcaserin was evaluated in a double-blind study in 
which 3182 obese or overweight adults (mean baseline BMI 
36.2 kg/m2) received 10 mg lorcaserin twice daily or placebo 
for 52 weeks. At week 52, patients in the placebo group 
continued on this treatment, but patients in the lorcaserin 
group were randomly reassigned to receive either placebo or 
lorcaserin. At the end of the first 52 weeks, 47.5% of patients 
in the lorcaserin group and 20.3% in the placebo group had 
lost $5% of their body weight (P , 0.001). Among patients 
who received lorcaserin during year 1 and lost $5% of their 
baseline weight, the loss was maintained by 67.9% of those 
who continued on lorcaserin during year 2 versus 50.3% of 
those rerandomized to placebo.101 However, administration of 
lorcaserin was associated with the development of neoplasms 
in rats and an FDA advisory panel recommended against 
its approval. The FDA accepted this recommendation and 
requested more information addressing this issue.100
Tesofensine is a noradrenaline, dopamine, and serotonin 
reuptake inhibitor and it has been evaluated for treatment 
of obesity in a Phase II, randomized, double-blind, placebo-
controlled trial that included 203 obese patients with mean 
baseline BMI of 30 to #40 kg/m2 who were prescribed tes-
ofensine 0.25 mg, 0.5 mg, or 1.0 mg/day or placebo plus an 
energy-restricted diet for 24 weeks. After 24 weeks, diet and 
placebo resulted in a 2.0% weight loss versus 4.5%, 9.2%, and 
10.6%, respectively for 0.25 mg, 0.5 mg, and 1.0 mg/day tes-
ofensine (P , 0.0001).102 Further development of this agent 
has been halted while the manufacturer, NeuroSearch (Bal-
lerup, Denmark), seeks a partner to continue commercial-
ization.103 Development of another agent that demonstrated 
efficacy in Phase II trials, velneperit (S-2367), a selective 
Figure  2  Differences  (with  95%  confidence  intervals  [CI])  between  long-acting 
analogs and neutral protamine Hagedorn insulin in the effects on body mass index at 
endpoint in clinical trials of patients with type 1 or type 2 diabetes mellitus.
Notes: Used with permission from Diabetes Research and Clinical Practice, vol 81, Pages 
184–189, M Monami, N Marchionni, E Mannucci. Long-acting insulin analogues versus 
NPH human insulin in type 2 diabetes: a meta-analysis. © Copyright Elsevier 2008.79
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  neuropeptide Y Y5-receptor antagonist, has been   discontinued 
due to anticipated difficulties in gaining approval in the US 
and European Union.104,105
The combinations of bupropion plus naltrexone, bupro-
pion plus zonisamide, and topiramate plus phentermine have 
all been assessed for treatment of obesity, but none have 
been approved by the FDA. The combination of bupropion, 
which is approved for depression and smoking cessation, and 
naltrexone, an opioid receptor antagonist approved for opi-
oid and alcohol addiction, was assessed for the treatment of 
obesity.106 When added to diet and exercise this combination 
has been shown to result in a loss of 9.3% of body weight 
(versus 5.1% among patients who received placebo, diet, and 
exercise; P , 0.001) over 56 weeks among obese patients.107 
In February 2011, however, the FDA issued a letter noting 
concern about the cardiovascular safety profile of naltrexone/
bupropion when used long-term in a population of overweight 
and obese subjects, and requested a preapproval safety 
study.108 The combination of bupropion with the antiepileptic 
drug zonisamide has demonstrated efficacy for decreasing 
body weight in Phase II trials, but it has not yet progressed 
to Phase III studies.109 Phentermine has been studied in 
combination with low-dose topiramate, an antiepileptic agent 
that is also used as a preventive treatment for migraines. 
Clinical trials with the phentermine/topiramate combination 
have demonstrated up to an 11% decrease in body weight 
when administered to obese patients.110 In October 2010, 
however, the FDA rejected the combination and required 
Table 3 Pharmacotherapy for obesity in the USA





5HT-releasing agent and reuptake  
inhibitor/norepinephrine- 
releasing agent




Fenfluramine withdrawn  




5HT-releasing agent and reuptake 
inhibitors
Cardiac valvulopathy and  
pulmonary hypertension
3.0% Both withdrawn in 1997
Sibutramine Norepinephrine/serotonin  
reuptake inhibitor; induces  
satiety/increases energy  
expenditure
BP and pulse elevations,  
Mi, and stroke risk
3.7%–5.0% Withdrawn in 2010
Phentermine resin,  
diethylpropion
Norepinephrine releasing agents BP and pulse elevations 8.1%  
(36 weeks)
Approved in 1960s  
for short-term use
Mazindol Norepinephrine reuptake  
inhibitor
BP and pulse elevations  2%–10%  
(12 weeks)
Discontinued in 1999




Withdrawn from OTC  
market in 2000
Orlistat Pancreatic and gastric lipase  
inhibitor
None known 2.9%–3.4% FDA approved in 1999  
for long-term use
Rimonabant Endocannabinoid receptor  
type 1 blocker
NA 5.0% Not approved 2007,  
psychiatric side effects cited
Topiramate/phentermine GABA receptor modulation BP and pulse elevations 8.6% Not approved in 2010, 
cardiovascular effects  
and teratogenicity cited
Bupropion/naltrexone Dopamine, norepinephrine  
reuptake inhibitor/opioid  
antagonists
BP elevation 4.8% Not approved in 2010, FDA 
requesting preapproval  
long-term cardiovascular study
Lorcaserin 5HT2c receptor agonist Possible valvulopathy 3.6% Not approved in 2010, breast  
tumors in animals cited
Bupropion/zonisamide Dopamine norepinephrine  
reuptake inhibitor/sodium  
channel modulator
BP elevation 6.1% Phase iiB/iii
Pramlintide/metreleptin incretin and adipose tissue  
hormone with satiety signal in  
hypothalamus
NA 9.2%  
(28 weeks)
Phase iiB
Liraglutide GLP-1 agonist NA 4.5%  
(20 weeks)
Phase iiB/iii
Notes: *Mean weight loss in excess of placebo as percentage initial body weight across 1 year, unless otherwise specified. Used with permission from Apovian and Gokce.89
Abbreviations: BP, blood pressure; Mi, myocardial infarction; OTC, over the counter; GLP-1, glucagon-like peptide-1; FDA, Food and Drug Administration; NA, not 
available; GABA, gamma-aminobutyric acid; 5HT, 5-hydroxytryptamine.
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the manufacturer, VIVUS, Inc, (Mountain View, CA) to 
provide more evidence regarding the elevation of heart 
rate associated with phentermine, including the likelihood 
that it increases the risk for major adverse cardiovascular 
events, as well as mandating a comprehensive assessment 
of the product’s potential to cause birth defects associated 
with topiramate.111 A study published in 2008 reported that 
although the number of adverse outcomes was low among 
pregnant individuals exposed to topiramate, the overall rate 
of oral clefts in newborns was eleven times the background 
rate, raising concerns about congenital malformation among 
those receiving topiramate polytherapy.112 In March 2011, the 
FDA informed the public that new data revealed an increased 
risk for development of cleft lip and/or cleft palate (oral 
clefts) among infants born to women who were treated with 
topiramate.113
Neurohormonal approaches have demonstrated efficacy in 
the treatment of obesity and may have less risk for significant 
toxicity than agents aimed primarily at the central nervous 
system. Leptin is a neurohormone secreted by adipocytes, 
and leptin-deficient humans exhibit severe hyperphagia and 
profound obesity. Amylin is another peptide hormone that is 
secreted with insulin from pancreatic β-cells and the amylin 
analog pramlintide increases satiation and reduces food 
intake.114 The combination of pramlintide and metreleptin is 
being developed as a treatment for obesity. A 24-week, ran-
domized, double-blind trial included 177 obese or overweight 
subjects (mean baseline BMI 32.0 kg/m2) who received pram-
lintide (180 µg twice daily for 2 weeks, and 360 µg twice 
daily thereafter) and diet (40% calorie deficit) for 4 weeks. 
Those who achieved 2%–8% weight loss over 4 weeks 
were randomized to 20 weeks of treatment with metreleptin 
(5 mg twice daily), pramlintide (360 µg twice daily), or 
combination of the two agents at the stated doses. Weight 
reductions with the three treatments were −8.2%, −8.4%, 
and −12.7%, respectively. Combination treatment was sig-
nificantly more effective than either metreleptin (P , 0.01) 
or pramlintide (P , 0.001) monotherapy.114
The beneficial effects of liraglutide on body weight 
(see incretin-based treatments section) have prompted its 
development for the treatment of obesity. A double-blind, 
placebo-controlled 20-week trial included 564 obese indi-
viduals (mean baseline BMI 30–40 kg/m2) who were ran-
domized to liraglutide doses of 1.2 mg, 1.8 mg, 2.4 mg, or 
3.0 mg/day, placebo, or orlistat (120 mg/day). All subjects 
also had an energy-deficit diet and increased their physical 
activity. Mean weight losses with liraglutide 1.2 mg, 1.8 mg, 
2.4 mg, and 3.0 mg were 4.8 kg, 5.5 kg, 6.3 kg, and 7.2 kg, 
respectively compared to 2.8 kg with placebo and 4.1 kg 
with orlistat.115
Bariatric surgery
Four types of bariatric surgery are used most often in the US. 
These include adjustable gastric band, Roux-en-Y gastric 
bypass (RYGB), biliopancreatic diversion with a duodenal 
switch, and vertical sleeve gastrectomy (Figure 3).116 The 
adjustable gastric band limits food intake by placing a small 
band around the top of the stomach to produce a small pouch. 
The outlet size is controlled by a circular balloon inside the 
band that can be inflated or deflated with saline solution. 
The RYGB restricts food intake and also reduces absorption. 
Food intake is limited by a small pouch and absorption of 
food is reduced by routing food directly from the pouch into 
the small intestine and thus bypassing most of the stomach, 
duodenum, and upper intestine. The biliopancreatic diver-
sion with a duodenal switch removes a large portion of 
the stomach to promote smaller meal sizes and decreases 
absorption by rerouting food away from much of the small 
intestine and by rerouting bile and other digestive juices. 
The vertical sleeve gastrectomy involves removing a large 
portion of the stomach to create a gastric sleeve that remains 
connected to a very short segment of the duodenum, which is 
then directly connected to a lower part of the small   intestine. 
This operation makes the distance between the stomach 
and colon much shorter after this operation, thus promoting 
malabsorption.116
Eight clinical trials of patients who have undergone 
gastric bypass surgery have shown that this intervention is 
associated with a 99% to 100% prevention of diabetes in 
individuals with IGT and an 80% to 90% clinical resolution of 
diagnosed T2DM.117 A systematic review and meta-analysis 
summarizing 136 studies published in English between 1990 
and 2003 that included .22,000 patients who underwent bar-
iatric surgery (73% women; mean BMI 47 kg/m2) indicated 
complete resolution of T2DM (defined as discontinuation 
of all diabetes-related medications and blood glucose levels 
within the normal range) in 77% of cases. An average weight 
loss of 41 kg (approximately 65% of the excess weight) was 
recorded among patients with resolution of diabetes.118 The 
effectiveness of bariatric surgery in decreasing body weight 
and returning patients to euglycemia and normal insulin 
levels has prompted the suggestion that the small bowel may 
play a key role in the pathophysiology of T2DM.119
The ADA 2011 Standards of Medical Care in Diabetes sup-
port gastric reduction surgery, stating that it can be effective for 
inducing weight loss among individuals with severe obesity.26 
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A Diabetes Surgery Summit Position Statement likewise 
recognizes the legitimacy of surgical procedures such as gas-
tric bypass for treatment of diabetes among certain patients, 
and notes that clinical trials aimed at determining the role 
of surgery for those with less severe obesity and diabetes 
should be a priority.120
Several new devices have been developed (and adapted) 
to facilitate the endoluminal approach to bariatric   procedures. 
An endoluminal bariatric sleeve that is open at both ends 
and is intended to mimic the duodenal and proximal 
jejunal bypass impact of an RYGB produced an average 
weight loss of 23.6% in a group of 10 patients followed 
for 12 weeks.121 In December 2010 the FDA approved a 
gastric band (LAP-BAND® Adjustable Gastric Banding 
System; BioEnterics Corporation, Carpinteria, CA; initially 
approved in 2001) for weight reduction in obese patients with 
a BMI $ 35 kg/m2 and in those with BMI . 30 kg/m2 who 
have one or more comorbid conditions, finding that benefits 
of such procedures outweigh the risks.122 The effectiveness 
of the LAP-BAND® in patients with T2DM is supported by 
results from 413 patients who were followed for $1 year 
postsurgery. Resolution of diabetes was observed in 66% at 
1-year and 80% at 2-year follow-up. The mean HbA1c value 
declined from 7.25% preoperatively to 5.58% at 2 years after 
surgery. The reduction in excess weight was 39.2% at 1 year 
and 52.6% at 2 years.123
Results from the Swedish Obese Subjects study of 4047 
obese patients has provided insight into the long-term effects 
of bariatric surgery. Ten-year follow-up of these patients 
showed weight losses from baseline of 25%, 16%, and 
14%, respectively for patients treated with gastric bypass, 
vertical-banded gastroplasty (stapling), and banding. Study 
results also indicated significantly decreased mortality risk 
for patients who underwent surgery versus controls (HR 
0.76; P = 0.04).124
The benefits of bariatric surgery on glycemic control may 
result, at least in part, from their effects on the incretin system. 
Results from a study of 41 obese patients with T2DM under-
going either bypass, banding, or very-low-calorie diet who 
were followed for up to 42 days indicated that patients who 
underwent bypass surgery had increased GLP-1 responses to 
meals (P , 0.05).125 Similarly, a study of 16 obese patients 
with T2DM who received either RYGB or gastric-restrictive 
surgery (laparoscopic adjustable gastric band or laparoscopic 
sleeve gastrectomy) indicated that those treated with RYGB 
had significant increases in insulin secretion, GLP-1 levels, 
and β-cell sensitivity to glucose (P , 0.05).126 It has been sug-
gested that RYGB and other malabsorptive procedures, such 
as biliopancreatic diversion, improve glucose homeostasis by 
increasing delivery of unabsorbed nutrients to the distal gut 
and thus increasing secretion of GLP-1.127 Further support for 
the view that hormonal effects, independent of weight loss, 
may underlie improvements in glycemic control in patients 
undergoing bariatric surgery is that this effect is observed in 
days to weeks after surgery, prior to the occurrence of sig-
nificant weight loss.128 The suggestion that   hormonal effects 
Figure 3 Commonly used bariatric surgery procedures.
Notes: From Weight Control Information Network and National Institute of Diabetes and Digestive and Kidney Diseases.116 image used with permission from Walter Pories, 
MD, FACS. ©Copyright University of North Carolina.
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associated with nutrient delivery to the distal gut and elevated 
GLP-1 secretion contributes to improved glycemic control is 
supported by results of studies which have shown that RYGB 
improved glucose control versus restrictive procedures despite 
equivalent weight loss. Results from a comparison of RYGB 
versus adjustable gastric banding indicated better higher post-
meal GLP-1 and glucose control with the former procedure 
despite equivalent postsurgical BMI in the two groups of 
patients.129 Other gastrointestinal hormones may also play a 
role in the weight loss associated with bariatric surgery. Pep-
tide YY3–36 is involved in food intake and clinical trial results 
have indicated that gastric bypass surgery, but not gastric 
banding, increases levels of this peptide.130 It has also been 
shown that gastric bypass surgery, but not diet-induced weight 
loss, increases levels of oxyntomodulin, and it has been sug-
gested that elevation of this hormone may be necessary for the 
improved glucose control associated with bariatric surgery.131
Economic considerations
Use of nonpharmacologic interventions and newer therapies 
(eg, incretin-based treatments, insulin detemir) and surgical 
intervention in an effort to lower body weight or prevent 
weight gain in patients with diabetes has the potential to 
increase the cost of care, although results from pharmaco-
economic studies have indicated long-term economic benefit 
of these approaches. It has been noted that dietary programs 
aimed at decreasing obesity, such as the Dietary Approaches to 
Stop Hypertension program, are effective for lowering weight 
and improving other cardiovascular risk factors and have low 
cost.132 Projection of long-term treatment outcomes supports 
the cost-effectiveness of both liraglutide and exenatide for 
the treatment of T2DM.133,134 Pharmacoeconomic analysis 
has also indicated that treatment of patients with T2DM 
using insulin detemir is cost-effective versus NPH insulin.135 
Bariatric surgery has been reported to be cost-effective versus 
nonsurgical interventions in severely obese patients.136
Conclusion
Overweight and obesity are common in the US population. 
Obesity increases the risk for T2DM as well as that for 
complications in people with the disease. Close attention to 
diet and lifestyle can significantly decrease the frequency of 
T2DM in high-risk patients and help control blood glucose 
in patients with the disease. These interventions have also 
been shown to be effective for reversing T2DM in patients 
diagnosed with this disease. Treatment for diabetes evolves 
with disease progression, and clinicians must consider effects 
on weight when selecting medications. Among older agents, 
metformin and acarbose have the lowest risk for weight gain. 
Clinical trial results have also consistently demonstrated that 
treatment with GLP-1 receptor agonists lowers weight, and 
DPP-4 inhibitors are weight-neutral in patients with T2DM. 
Most patients with T2DM ultimately require insulin treat-
ment, and insulin analogs have lower liability for weight 
gain than human insulin. This benefit has been demonstrated 
most consistently for insulin detemir and is less clear for 
insulin glargine and the rapid-acting insulin analogs. Surgical 
therapies aimed at treating obesity can improve metabolic 
control and can even prevent T2DM in some individuals. 
Bariatric surgery remains the most effective treatment for 
obesity, and research is elucidating its unique effectiveness 
and it can also reverse diabetes in patients with T2DM. The 
factors responsible for this resolution before actual weight 
loss may lie in the secretion of incretin hormones. Overall, 
results summarized in this review underscore the point that 
changes in lifestyle and diet are highly effective for control-
ling body weight and reversing T2DM and should be empha-
sized as first steps in patient management. For patients who 
cannot achieve significant and sustained weight loss with 
these approaches, careful selection of antidiabetes therapy 
and additional surgical intervention, if necessary, can assist 
in the control of body weight.
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